Psychoactive drugs

Klarisana Brings Revolutionary Mental Health Treatment to Westminster, Colorado

Retrieved on: 
Monday, November 9, 2020
Drugs, Psychoactive drugs, Branches of biology, Ketones, Amines, Antidepressants, Nicotinic antagonists, Sedatives, Ketamine, Mental health, Pain, Medicaid

With their innovative use of intramuscular ketamine treatment, Klarisana stands poised to make this cutting-edge treatment more accessible than ever before.

Key Points: 
  • With their innovative use of intramuscular ketamine treatment, Klarisana stands poised to make this cutting-edge treatment more accessible than ever before.
  • The team at Klarisana recognize that now more than ever, the rising rates of those struggling with mental health cannot be ignored.
  • Klarisana is the first ketamine-based provider to work in-network with Medicaid in the state of Colorado, making this revolutionary treatment accessible to a cascade of new people who otherwise might not have received this innovative treatment for their condition.
  • Since 2015, Klarisana have been pioneers of ketamine therapy for the treatment of mental health and pain conditions.

Nextleaf Solutions Signs Cannabis Extraction Agreement with Eve & Co

Retrieved on: 
Monday, November 9, 2020
OTC Markets Group, Medco, Cannabis concentrate, Cannabis, Psychoactive drugs, Branches of biology

VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nextleaf Solutions Ltd. ("Nextleaf Solutions", "OILS", or the "Company") (CSE: OILS) (OTCQB: OILFF), Canadas most innovative cannabis extractor, is pleased to announce that its wholly-owned subsidiary Nextleaf Labs Ltd. (Nextleaf Labs), a Health Canada licensed standard processor, has entered into a Cannabis Extraction Agreement (the Agreement) with Natural MedCo Ltd.(NMC), a wholly-owned subsidiary of Eve & Co Incorporated (Eve & Co) (TSX-V: EVE) (OTCQB: EEVVF).

Key Points: 
  • VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nextleaf Solutions Ltd. ("Nextleaf Solutions", "OILS", or the "Company") (CSE: OILS) (OTCQB: OILFF), Canadas most innovative cannabis extractor, is pleased to announce that its wholly-owned subsidiary Nextleaf Labs Ltd. (Nextleaf Labs), a Health Canada licensed standard processor, has entered into a Cannabis Extraction Agreement (the Agreement) with Natural MedCo Ltd.(NMC), a wholly-owned subsidiary of Eve & Co Incorporated (Eve & Co) (TSX-V: EVE) (OTCQB: EEVVF).
  • Pursuant to the Agreement, NMC will provide cannabis biomass to be processed into distilled THC and CBD oils at Nextleafs closed-loop extraction plant in Metro Vancouver.
  • We are excited for the opportunity to support the launch of Eve & Cos female-focussed cannabis 2.0 product lines in Canada, stated Nextleaf Solutions CFO, Charles Ackerman.
  • Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR

Retrieved on: 
Monday, November 9, 2020
Drugs, Psychoactive drugs, Clinical medicine, Euphoriants, Stimulants, Anorectics, TAAR1 agonists, Substituted amphetamines, Nasal administration, Dextroamphetamine, Amphetamine, Tolerability

We are pleased with the results gained from our first human abuse liability study which demonstrated that recreational drug abusers preferred ADAIR less when compared to currently available IR dextroamphetamine, a positive signal when trying to reduce stimulant abuse.

Key Points: 
  • We are pleased with the results gained from our first human abuse liability study which demonstrated that recreational drug abusers preferred ADAIR less when compared to currently available IR dextroamphetamine, a positive signal when trying to reduce stimulant abuse.
  • Additionally, the data give us confidence in the design of our upcoming pivotal intranasal abuse study which will evaluate ADAIR with a larger number of subjects, expected to initiate before year end, commented David Baker, President & Chief Executive Officer of Vallon.
  • The 16-subject proof-of-concept intranasal human abuse study (VAL-103) demonstrated that intranasal administration of manipulated ADAIR was generally well tolerated, with all adverse events considered mild or moderate, and no new safety or tolerability signals identified.
  • In addition, snorting manipulated ADAIR was more unpleasant than snorting crushed dextroamphetamine based on the Subject-Rated Assessment of Intranasal Irritation (SRAII) scale.

Jushi Holdings Inc. Announces Provisional License for Medical Cannabis Cultivation in Portugal

Retrieved on: 
Monday, November 9, 2020
Entheogens, Euphoriants, Medicinal plants, Jushi, Cannabis, Psychoactive drugs, Plants, Branches of biology

The Beja facility will be constructed with a closed environment, offering the environmental control of indoor cultivation and the sun utilization of outdoor cultivation, allowing Jushi Europe to sustainably produce high-quality EU-GMP certified medical cannabis.

Key Points: 
  • The Beja facility will be constructed with a closed environment, offering the environmental control of indoor cultivation and the sun utilization of outdoor cultivation, allowing Jushi Europe to sustainably produce high-quality EU-GMP certified medical cannabis.
  • Once the final license is granted, Jushi Europe will commence exporting EU-GMP medical cannabis to licensed foreign importers, in accordance with INFARMED guidelines.
  • Jushi Europe's strategy is focused on building large-scale production in Portugal for export to the European medical cannabis market.
  • Jushi Europe represents geographic diversification of the Jushi portfolio and an entrance into early-stage cannabis markets through long-term investments.

Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference

Retrieved on: 
Monday, November 9, 2020
Psychoactive drugs, Antidepressants, Hypnotics, Seltorexant, Chemical compounds, 5-HT2A antagonists, Drugs, Roluperidone

WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual London Healthcare Conference on November 17, 2020 at 12:55 p.m. GMT (7:55 a.m. EST).

Key Points: 
  • WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual London Healthcare Conference on November 17, 2020 at 12:55 p.m. GMT (7:55 a.m. EST).
  • The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Companys web site, http://ir.minervaneurosciences.com .
  • Minervas portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinsons disease.
  • Minervas common stock is listed on the NASDAQ Global Market under the symbol NERV.For more information, please visit www.minervaneurosciences.com .

2020 Worldwide 1,4 Butanediol Market - Competitive Analysis and Leadership Study - ResearchAndMarkets.com

Retrieved on: 
Monday, November 9, 2020
Chemicals, Plastics, Manufacturing, Alkanediols, Psychoactive drugs, Drugs, Neurochemistry, 1,4-Butanediol, Butanediol

The "Worldwide 1,4 Butanediol Competitive Analysis and Leadership Study" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Worldwide 1,4 Butanediol Competitive Analysis and Leadership Study" report has been added to ResearchAndMarkets.com's offering.
  • Major players in 1,4 Butanediol market have diversified product portfolios, strong geographical reach, and have made several strategic initiatives.
  • The dynamics of the 1,4 Butanediol market extends beyond routine macro-economic elements of supply and demand.
  • Using its proprietary research methodology, the analyst has developed a comparative analysis tool, the 'Leadership Quadrant,' which identifies leaders, contenders, visionaries, and specialists in the 1,4 Butanediol market and rates each 1,4 Butanediol producer.

Icanic Brands Congratulates States on Successfully Passing Cannabis Legalization Measures

Retrieved on: 
Monday, November 9, 2020
Cannabis smoking, Psychoactive drugs, Cannabis, Entheogens, Euphoriants, Effects of cannabis

The Company believes that California will always hold a significant influence over the cannabis industry and be looked upon as a leader in the space.

Key Points: 
  • The Company believes that California will always hold a significant influence over the cannabis industry and be looked upon as a leader in the space.
  • By continuing to be a leader in the most competitive space with the most discerning consumer, it positions Icanic Brands well to take that brand IP and expertise to other states when legal and opportunities present themselves.
  • We look forward to the opportunity to provide the residents of these states with the best pre-roll experience of their lives.
  • Icanic Brands Company, Inc. is a leading cannabis branded products manufacturer based in California & Nevada, the largest and most competitive cannabis markets in the world.

Philippines Tobacco Report 2020: Overview of the Current Regulations for Heated Tobacco and Oral Tobacco Products - ResearchAndMarkets.com

Retrieved on: 
Monday, November 9, 2020
Tobacco, Retail, Psychoactive drugs, Cigarettes, Electronic cigarettes, Summer, Tobacco products, Smoking cessation, Tobacco, Cigarette, Electronic cigarette, Heated tobacco product

The "Philippines Tobacco Report: Will the Possible Changes to Regulations in the Philippines Affect Your Business?"

Key Points: 
  • The "Philippines Tobacco Report: Will the Possible Changes to Regulations in the Philippines Affect Your Business?"
  • This report provides a detailed overview of the current regulations in place for both heated tobacco and oral tobacco products in the Philippines.
  • Both heated tobacco and oral tobacco products are subject to many of the existing regulations that govern traditional cigarettes, while nicotine pouches are covered under general consumer laws.
  • If you are interested in the Philippines and its current regulatory regime for heated tobacco and oral products then this is the report for you.

Golden Leaf Holdings Announces Resignation of President Stanley Grissinger

Retrieved on: 
Friday, November 6, 2020
Cannabis, Cannabis smoking, Entheogens, Euphoriants, Psychoactive drugs, Alliance One International

TORONTO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (CSE:GLH) (OTCQB:GLDFF) (Golden Leaf or the Company), a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, announces the resignation of Stanley Grissinger as President.

Key Points: 
  • TORONTO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (CSE:GLH) (OTCQB:GLDFF) (Golden Leaf or the Company), a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, announces the resignation of Stanley Grissinger as President.
  • Effective November 2, 2020 Stanley Grissinger has resigned as President of the Company in order to pursue other opportunities.
  • Golden Leaf CEO Jeff Yapp will assume the role of President.
  • Golden Leaf Holdings is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with seven dispensaries in Portland, Oregon.

Kannalife, Inc. Rebrands as Neuropathix, Inc. and Unveils New Ticker Symbol

Retrieved on: 
Friday, November 6, 2020
Psychoactive drugs, Entheogens, Euphoriants, Anti-inflammatory, MDMA

Neuropathix, Inc., previously known as Kannalife, Inc., is a well-known pioneer in cannabinoid therapeutics and has been covered by global news media for the past ten (10) years.

Key Points: 
  • Neuropathix, Inc., previously known as Kannalife, Inc., is a well-known pioneer in cannabinoid therapeutics and has been covered by global news media for the past ten (10) years.
  • To coincide with this rebranding, the Company has released a new corporate website at www.neuropathix.com .
  • Atopidine is Neuropathix novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing.
  • The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.